(NASDAQ: PHVS) Pharvaris Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Pharvaris Nv's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PHVS's revenue for 2026 to be $660,566,635, with the lowest PHVS revenue forecast at $660,566,635, and the highest PHVS revenue forecast at $660,566,635. On average, 4 Wall Street analysts forecast PHVS's revenue for 2027 to be $4,278,685,177, with the lowest PHVS revenue forecast at $1,070,656,561, and the highest PHVS revenue forecast at $5,870,766,810.
In 2028, PHVS is forecast to generate $13,710,534,531 in revenue, with the lowest revenue forecast at $9,984,584,014 and the highest revenue forecast at $17,436,485,048.